Zobrazeno 1 - 10
of 353
pro vyhledávání: '"R Holzer"'
Autor:
Jonathan T. Sims, Josh Poorbaugh, Ching-Yun Chang, Timothy R. Holzer, Lin Zhang, Sarah M. Engle, Stephanie Beasley, Thompson N. Doman, Lynn Naughton, Richard E. Higgs, Nicole Kallewaard, Robert J. Benschop
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background A thorough understanding of a patient’s inflammatory response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is crucial to discerning the associated, underlying immunological processes and to the selec
Externí odkaz:
https://doaj.org/article/bdd024c53d764522a92238a2eb84f962
Autor:
Kyle M. Hernandez, Kelli S. Bramlett, Phaedra Agius, Jonathan Baden, Ru Cao, Omoshile Clement, Adam S. Corner, Jonathan Craft, Dennis A. Dean, Jonathan R. Dry, Kristina Grigaityte, Robert L. Grossman, James Hicks, Nikki Higa, Timothy R. Holzer, Jeffrey Jensen, Donald J. Johann, Sigrid Katz, Anand Kolatkar, Jennifer L. Keynton, Jerry S.H. Lee, Dianna Maar, Jean-Francois Martini, Christopher G. Meyer, Peter C. Roberts, Matt Ryder, Lea Salvatore, Jeoffrey J. Schageman, Stella Somiari, Daniel Stetson, Mark Stern, Liya Xu, Lauren C. Leiman
Publikováno v:
The Journal of Molecular Diagnostics. 25:143-155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::273666f365539174801b7e62c812d195
https://doi.org/10.1016/j.jmoldx.2022.12.003
https://doi.org/10.1016/j.jmoldx.2022.12.003
Publikováno v:
Cancer Cell International, Vol 17, Iss 1, Pp 1-12 (2017)
Abstract Background Clinically relevant predictive biomarkers to tailor anti-angiogenic therapies to breast cancer (BRC) patient subpopulations are an unmet need. Methods We analyzed tumor vascular density and VEGFR2 protein expression in various sub
Externí odkaz:
https://doaj.org/article/8143f028811a47df9aa322e4180d0112
Autor:
George Simon, Mayer Fishman, Funda Meric-Bernstam, Timothy R. Holzer, Aejaz Nasir, Sunil K. Kadam, Valérie André, Sophie Callies, Les Brail, Aung Naing, Jennifer Wheler, Yun Oh, Razelle Kurzrock, David S. Hong
CCR Translation for This Article from A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e3a97d95d71f68d35418f84b3673e1
https://doi.org/10.1158/1078-0432.22443176.v1
https://doi.org/10.1158/1078-0432.22443176.v1
Autor:
George Simon, Mayer Fishman, Funda Meric-Bernstam, Timothy R. Holzer, Aejaz Nasir, Sunil K. Kadam, Valérie André, Sophie Callies, Les Brail, Aung Naing, Jennifer Wheler, Yun Oh, Razelle Kurzrock, David S. Hong
PDF file - 69K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b52cd6d336625819e15d8210fb3fad2
https://doi.org/10.1158/1078-0432.22443173.v1
https://doi.org/10.1158/1078-0432.22443173.v1
Autor:
George Simon, Mayer Fishman, Funda Meric-Bernstam, Timothy R. Holzer, Aejaz Nasir, Sunil K. Kadam, Valérie André, Sophie Callies, Les Brail, Aung Naing, Jennifer Wheler, Yun Oh, Razelle Kurzrock, David S. Hong
Purpose: The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors. This phase I study sought an appropriate LY2275796 dose in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89c0797f6deee104cc33787ce6e36608
https://doi.org/10.1158/1078-0432.c.6519698.v1
https://doi.org/10.1158/1078-0432.c.6519698.v1
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c671bc65b6856e2a675f8baf6d6b7e3
https://doi.org/10.1093/cid/ciab912
https://doi.org/10.1093/cid/ciab912
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163d2b1d9fb708ea8c2b335a117a4a4b
https://doi.org/10.1056/nejmoa2102685
https://doi.org/10.1056/nejmoa2102685
Autor:
Timothy R. Holzer, Sameera R. Wijayawardana, Gerard J. Oakley, Narasimha Marella, Holly Kay Cannon, Jessica A. Roseberry Baker, Anthony N. Sireci, Juraj Bodo, Joel D. Cook, Tyler J Marquart, Andrew E. Schade, Eric D. Hsi, Leslie O'Neill Reising
Publikováno v:
Archives of Pathology & Laboratory Medicine. 146:351-359
Context.— RET gene fusions are oncogenic drivers in nonsmall cell lung cancer and nonmedullary thyroid cancer. Selpercatinib (RETEVMO), a targeted inhibitor of RET, was approved by the US Food and Drug Administration for the treatment of RET fusion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66900a002a5c3812453106a1661a00d2
https://doi.org/10.5858/arpa.2020-0376-oa
https://doi.org/10.5858/arpa.2020-0376-oa
Publikováno v:
NSG2022 28th European Meeting of Environmental and Engineering Geophysics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb3907037d43dcedd0460373f86a3685
https://doi.org/10.3997/2214-4609.202220160
https://doi.org/10.3997/2214-4609.202220160